[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [2] Chen Y, Qi Y, Wang K.Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress[J]. Front Oncol, 2023, 13: 1169010. [3] Sparano JA.Neoadjuvant Systemic Therapy for Breast Cancer: Searching for More Effectively Curative Therapies[J]. JAMA Oncol, 2018, 4(3): 293-295. [4] Ruano Pérez R, Rebollo Aguirre AC, García-Talavera San Miguel P, et al. Review of the role of the sentinel node biopsy in neoadjuvant chemotherapy in women with breast cancer and negative or positive axillary node at diagnosis[J]. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2018, 37(1): 63-70. [5] Cortazar P, Zhang L, Untch M, et al.Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172. [6] Gao G, Wang Z, Qu X, et al.Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2020, 20(1): 179. [7] Salgado R, Denkert C, Demaria S, et al.The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014[J]. Ann Oncol, 2015, 26(2): 259-271. [8] Stanton SE, Adams S, Disis ML.Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review[J]. JAMA Oncol, 2016, 2(10): 1354-1360. [9] Bear HD, Anderson S, Brown A, et al.The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol, 2003, 21(22): 4165-4174. [10] Asano Y, Kashiwagi S, Goto W, et al.Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden[J]. BMC Cancer, 2017, 17(1): 888. [11] Lee HJ, Seo JY, Ahn JH, et al.Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients[J]. J Breast Cancer, 2013, 16(1): 32-39. [12] Houssami N, Macaskill P, Von Minckwitz G, et al.Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy[J]. Eur J Cancer, 2012, 48(18): 3342-3354. [13] Haque W, Verma V, Hatch S, et al.Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2018, 170(3): 559-567. [14] Cortazar P, Geyer CE.Pathological complete response in neoadjuvant treatment of breast cancer[J]. Ann Surg Oncol, 2015, 22(5): 1441-1446. [15] Mao Y, Qu Q, Zhang Y, et al.The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis[J]. PLoS One, 2014, 9(12): e115103. [16] Hwang HW, Jung H, Hyeon J, et al.A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients[J]. Breast Cancer Res Treat, 2019, 173(2): 255-266. [17] Denkert C, Von Minckwitz G, Darb-Esfahani S, et al.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50. |